Kevin Crofton joined Creo Medical's board in July 2024 and is an accomplished business leader with over three decades of extensive international experience in the technology industry. He has a successful track record of driving innovation and generating profitable growth.

Most recently, Kevin was the CEO of Comet Holdings AG, a Swiss listed technology company, where he delivered significant shareholder value by driving greater customer engagement. Prior to this, he was CEO of SPTS Technologies where he led the PE backed management buyout and exit of the company to Orbotech, Inc., joining the team who subsequently sold the group to KLA-Tencor Corporation for $3.4bn. Kevin has also acted as Chairman of SEMI International and the UK Compound Semiconductor Applications Catapult.

Kevin holds an MBA in International Business from the American University, Washington DC, and a BS in Engineering (Aerospace) from Virginia Tech.

Kevin is a member of the Company's Audit Committee.

Craig was a founding angel investor in Creo Medical and became CEO in 2012.

Craig qualified with an MSc in Electronic Engineering from the University College of North Wales. Craig’s early career developed in the Middle East, working with large corporates delivering complex commercial projects. Craig has over 25 years’ experience in building international businesses from early stage through to significant scale. In January 1999, Craig joined a start-up software and hardware business where, as COO, he was part of a small team that grew the Company both organically and through acquisition, from a loss-making start-up to a profitable business delivering significant shareholder returns and an exit in 2007.

Craig is a Non-Executive Director of I.Q. Endoscopes Limited.

Chris is the founder of Creo Medical and has over 25 years’ experience in medical device innovation, design and development.

Chris holds a personal chair in the Medical Microwave Systems Research Group at Bangor University. Chris is a Fellow of the Royal Academy of Engineering, a Fellow of the Learned Society of Wales, a Fellow of the Institute of Physics, and a Fellow of the Institute of Engineering and Technology. He is also a Chartered Engineer, a Chartered Physicist and a Senior Member of the Institute of Electrical and Electronics Engineers. Chris is a Royal Academy of Engineering Visiting Professor at UCL, and an Honorary Professor in the School of Medicine at Cardiff University. 

Chris was awarded the Institute of Physics Katherine Burr Blodgett Gold Medal and Prize in 2019 for work on Creo’s CROMA Advanced Energy Platform technology and the Inaugural Junkosha Technology Innovator of the Year prize and award in 2022. He was recognised by the European Patent Office in 2023 as one of the 50 Leading Tech Voices to mark 50 years of the European Patent Convention.

Chris is a named inventor and lead author on over 1,500 worldwide granted patents, pending patents and international journal publications in the use of electromagnetic energy for medical applications.

David joined Creo as CCO in August 2020, having previously sat on Creo’s Board as a Non-Executive Director.

David provides leadership and strategic direction for Creo’s commercial divisions, overseeing all strategic global commercial activities.

David is an industry veteran within the MedTech sector, and his experience encompasses Gastroenterology, General and Orthopaedic Surgery, Pulmonology and Ear, Nose and Throat.

Prior to joining Creo, David was the President and CEO of PENTAX Americas and M&A Director of Hoya Corporation, Pentax Life Care Division. He brings significant operating and commercial experience, market understanding and a proven track record of achievement to Creo.  He has also previously sat on multiple MedTech boards over the years. 

He was awarded the American Society for Gastrointestinal Endoscopy President’s Award in 2010, recognising exceptional contributions to the society and its mission.

In 2011, Richard was part of the SPTS Technologies’ management team that, together with Bridgepoint Capital, acquired SPTS Technologies for $200m from Sumitomo Precision Products. In 2014, SPTS Technologies was acquired by Orbotech Ltd for more than $350m.

Prior to joining SPTS Technologies, Richard spent seven years at KPMG in audit.

Ivonne is Director of Investor Relations and Sustainability at Benchmark Holdings plc, an AIM listed aquaculture biotechnology company and a non-executive director and chair of the Remuneration Committee at Primary Health Properties plc.

Ivonne is also a trustee of La Vida, a UK registered charity which supports grassroots projects in the fields of education, environment and health throughout Latin America.

Ivonne holds a BSc in Engineering from Universidad Panamericana in Mexico and an MBA from the Wharton School of Business.

Ivonne is the Interim Chairs for Creo Medical's Audit Committee.

Brent has a record of success in growing and transforming businesses across a range of medical device specialities, including technologies, oncology interventions, surgical solutions and respiratory care.

Brent is recognised as a business leader of multiple innovative growth businesses focused on commercial optimisation, new product, technology and procedural introductions, global market entry and strategic M&A. Throughout his career in the USA, Brent has held a number of executive positions in large multinational Medtech companies, including Covidien (acquired by Medtronic), AngioDynamics and Nuvasive, working to successfully deliver revenue growth and shareholder value.  Brent is currently SVP for the Americas for Solventum, a major US health care company which span out of 3M in early 2024.

Brent holds a Bachelor of Business Administration from North Dakota State University.

Brent is Chair of the Company's Renumeration Committee.